TGFβ1 and TGFβ2 mRNA and protein expression in human bone samples

Abstract

Transforming growth factor beta is one of the most abundant growth factors stored in bone. It is known as a potent regulator of osteoblast proliferation and differentiation as well as of production extracellular matrix. We established a highly specific RT-PCR in combination with HPLC for detection and quantification of TGFbeta1 and TGFbeta2 mRNA expression in 89 human bone samples. Levels of TGFbeta1 protein ranged between 27 and 580 ng/g bone (mean 188 +/- 15 ng/g; n=75) and for TGFbeta2 between 7.2 and 35 ng/g bone (mean 14.3 +/- 2.1 ng/g; n=57). TGFbeta1 and TGFbeta2 protein concentrations and TGFbeta isoform mRNA expression in bone were not significantly different between the sexes. TGFbeta isoform mRNA expression as well as protein content in bone declined age dependently. TGFbeta1 and TGFbeta2 protein and mRNA expression were different in bone samples from different sites of the skeleton indicating in part the regulation by mechanical stimuli. In contrast to TGFbeta1, TGFbeta2 mRNA expression was significantly enhanced in osteoarthritic bone compared to unaffected bone. These data are in concordance to previous results concerning the expression of TGFbeta3 in bone. In conclusion, the data suggest distinct patterns' of expression of the TGFbeta isoforms under physiological and pathological conditions in bone.

PET with the89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models

“…Hepatic processing is often saturable and thus dose-dependent, thereby explaining why increased kidney uptake of 89 Zr-fresolimumab catabolites was seen only in the lowest 89 Zr-fresolimumab dose of 10 mg. The high bone uptake of 89 Zr-fresolimumab, compared with 111 In-IgG, can be the result of high TGF-b levels in bone (28). However, we cannot exclude that this is an artifact due to bone uptake of dissociated 89 Zr because we have also seen high bone uptake of 89 Zr-bevacizumab when compared with 111 In-bevacizumab (17).…”

Biphasic effects of TGFβ1 on BMP9-induced osteogenic differentiation of mesenchymal stem cells

“…Effective ossification and bone regeneration is required for many defects such as bony callus with long healing time and limited strength, which are probably related to the deficiency of collagen production and finite osteogenic ability (5,6). TGFβ1 is one of the most abundant TGF members and important growth regulators in bone (7). Unlike BMPs, TGFβ1 is unable to induce osteogenesis in mesenchymal multipotent cells (8).…”

Reaming in treatment of non-unions in long bones: cytokine expression course as a tool for evaluation of non-union therapy

“…TGF-ß1 plays an important role in bone metabolism and in the early phase of bone regeneration and remodelling [17]. Its function in bone regeneration is the recruitment of bone marrow mesenchymal stem cells (MSC) from the perivascular area to the resorbed bone surface, and it stimulates the MSC to develop into osteogenic cells for promoting new bone formation [29,32].…”